Lindbrook Capital, LLC Moon Lake Immunotherapeutics Transaction History
Lindbrook Capital, LLC
- $1.06 Billion
- Q1 2025
A detailed history of Lindbrook Capital, LLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Lindbrook Capital, LLC holds 4 shares of MLTX stock, worth $150. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4Holding current value
$150% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
161Shares Held
55.3MCall Options Held
481KPut Options Held
229K-
Bvf Inc San Francisco, CA19.8MShares$743 Million33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$320 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$112 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$104 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$55.6 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.39B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...